The role of maternal homocysteine concentration in placenta-mediated complications: findings from the Ottawa and Kingston birth cohort

Table 3 Summary of multivariable logistic regression analyses of the association between homocysteine and placenta-mediated complications, n = 7587 ^a

Outcome variable	Odds ratio (95% CI) ^b		p-value ^c
Any placenta-mediated complication (759 events ^d)
Homocysteine (linear)			0.0007
5 μmol/L increase	1.629	(1.227, 2.161)
SGA (512 events ^d)
Homocysteine (linear)			0.0010
5 μmol/L increase	1.756	(1.254, 2.458)
SGA < 5th percentile (221 events ^d)
Homocysteine (linear)			0.0012
5 μmol/L increase	2.022	(1.322, 3.092)
Preeclampsia (227 events)
Homocysteine (linear)			0.0736
5 μmol/L increase	1.546	(0.959, 2.491)
Severe preeclampsia (43 events)
Homocysteine (linear)			0.0595
5 μmol/L increase	1.762	(0.978, 3.177)
Placental abruption (68 events)
Homocysteine (linear)			0.9851
5 μmol/L increase	1.005	(0.590, 1.711)
Pregnancy loss (85 events)
Homocysteine (linear)			0.1586
5 μmol/L increase	1.392	(0.879, 2.206)

^aComplete results reported in Table 2: any placenta-mediated complication, Additional file 4, and Additional file 3: Table C.1: SGA, Table C.2: Preeclampsia, Table C.3: Placental abruption, and Table C.4: Pregnancy loss
^bModels adjusted for maternal age, race, education, parity, smoking, diabetes, BMI, hormonal birth control prior to conception, chronic hypertension, history of a placenta mediated complication, folic acid supplementation, serum folate, and gestational age at blood work
^cWald test of most meaningful hypotheses, pooled across multiple imputation datasets
^d79 Missing outcome values imputed

ISSN: 1471-2393